87150-13-8

Usage

Uses

Used in Organic Synthesis:
4-(1,3-Oxazol-5-yl)benzonitrile is utilized as a building block in organic synthesis for the creation of a variety of pharmaceuticals and agrochemicals. Its structural attributes facilitate its role in the synthesis of complex organic molecules, contributing to the development of new compounds with potential therapeutic or agricultural benefits.
Used in Pharmaceutical Research:
In pharmaceutical research, 4-(1,3-Oxazol-5-yl)benzonitrile serves as a key intermediate, enabling the design and synthesis of novel drug candidates. Its incorporation into molecular frameworks can lead to the discovery of new pharmaceuticals with improved efficacy and selectivity.
Used in Material Science:
4-(1,3-Oxazol-5-yl)benzonitrile also finds potential applications in the field of material science. Its unique chemical structure can be leveraged to develop new materials with specific properties, such as enhanced stability or reactivity, which can be beneficial in various technological applications.
Used as a Reagent in Chemical Reactions:
Furthermore, 4-(1,3-Oxazol-5-yl)benzonitrile functions as a reagent in a range of chemical reactions. Its participation in these reactions can lead to the formation of new compounds or the modification of existing ones, broadening the scope of chemical research and development.
Used in Chemical Reactions Industry:
4-(1,3-Oxazol-5-yl)benzonitrile is used as a reagent for facilitating specific chemical transformations in the chemical reactions industry. Its unique properties allow for the synthesis of new compounds or the modification of existing ones, contributing to the advancement of chemical processes and products.
Safety Considerations:
Given the potential toxicity and hazardous nature of 4-(1,3-Oxazol-5-yl)benzonitrile, it is imperative to adhere to proper safety precautions and handling procedures when working with 4-(1,3-Oxazol-5-yl)benzonitrile. This ensures the safety of personnel and the environment while maintaining the integrity of the research and development process.

InChI:InChI=1/C10H6N2O/c11-5-8-1-3-9(4-2-8)10-6-12-7-13-10/h1-4,6-7H

Upstream product

• 105-07-7 4-cyanobenzaldehyde 
• 156780-52-8 2-(4-methoxyphenyl)-1,3-oxazole 
• 288-42-6 oxazol 
• 623-00-7 4-bromobenzenecarbonitrile 
• 433332-27-5 2-[tris(propan-2-yl)silyl]-1,3-oxazole 
• 1186127-11-6 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(triisopropylsilyl)-1,3-oxazole 
• 29166-72-1 N,N,N′,N′-tetramethyl-N″-tert-butylguanidine 
• 38622-91-2 [(p-methylphenyl)sulfonylmethyl]isonitrile 

Downstream Products

• 1258619-27-0 4-[2-(3-phenylpropyl)-5-oxazolyl]benzonitrile 
• 672324-91-3 [4-(1,3-oxazol-5-yl)phenyl]methanamine 
• 1415114-09-8 3-((5-(isoquinolin-6-yl)oxazol-2-yl)amino)phenol 
• 1415114-74-7 4-methyl-N-(4-(oxazol-5-yl)benzyl)benzenesulfonamide 
• 1415114-75-8 N-(2,2-dimethoxyethyl)-4-methyl-N-(4-(oxazol-5-yl)benzyl)benzenesulfonamide 
• 1415114-12-3 N-(3-((5-(isoquinolin-6-yl)oxazol-2-yl)amino)phenyl)-1-phenylmethanesulfonamide 
• 1415114-24-7 N-(3-((5-(isoquinolin-6-yl)oxazol-2-yl)amino)phenyl)methanesulfonamide 
• 1552274-00-6 4-(3-cyclopentyl-3H-imidazol-4-yl)-benzonitrile 
• 1552274-16-4 4-{3-[2-(4-fluorophenyl)ethyl]-3H-imidazol-4-yl}-benzonitrile 
• 1552274-30-2 4-(3-cyclopropylmethyl-3H-imidazol-4-yl)benzonitrile 
• 55368-59-7 4,4'-(oxazole-2,5-diyl)dibenzonitrile 
• 911820-02-5 4-[2-(5-amino-2-methyl-phenylamino)-oxazol-5-yl]-benzo-nitrile 

Relevant academic research and scientific papers

Reaction Conditions for the Regiodivergent Direct Arylations at C2- or C5-Positions of Oxazoles using Phosphine-Free Palladium Catalysts

Two sets of reaction conditions for the regiodivergent C2- or C5- direct arylations of oxazole are reported. In both cases, phosphine-free catalysts and inexpensive bases were employed allowing the access to the arylated oxazoles in moderate to high yields. Using Pd(OAc)2/KOAc as catalyst and base, regioselective C5-arylations were observed; whereas, using Pd(acac)2/Cs2CO3 system, the arylation occurred at the C2-position of oxazole. The higher reactivity of C5-H bond of oxazole as compared to the C2-H bond in the presence of Pd(OAc)2/KOAc system is consistent with a concerted metalation deprotonation mechanism; whereas the C2-arylation likely occurs via a simple base deprotonation of the oxazole C2-position. Then, from these C2- or C5-arylated oxazoles, a second palladium-catalyzed direct C?H bond arylation affords 2,5-diaryloxazoles with two different aryl groups. We also applied these sequential arylations to the straightforward synthesis of 2-arylphenanthro[9,10-d]oxazoles via three C?H bond functionalization steps. The Ru-catalyzed C?H arylation of the aryl unit of 2-aryloxazoles is also described. (Figure presented.).

Improvement of the Van Leusen reaction in the presence of β-cyclodextrin: A green and efficient synthesis of oxazoles in water

An efficient approach for the synthesis of oxazoles through the Van Leusen reaction in the presence of β-cyclodextrin is described. In aqueous medium using β-cyclodextrin as a supramolecular catalyst, tosylmethyl isocyanide was deprotonated by triethylami

COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF THE ANDROGEN RECEPTOR

The present invention relates to bifunctional compounds, which find utility to degrade and (inhibit) Androgen Receptor. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds Androgen Receptor such that Androgen Receptor is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of Androgen Receptor. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of Androgen Receptor.

BENZOTHIOPHENE DERIVATIVES AS ESTROGEN RECEPTOR INHIBITORS

A compound of formula (I), or a pharmaceutically acceptable salt thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of the estrogen receptor, including degrading the estrogen receptor, the treatment of diseases and conditions mediated by the estrogen receptor.

Synthesis and biological activity of 5-(4-methoxyphenyl)-oxazole derivatives

5-(4′-Methoxyphenyl)-oxazole (MPO), originally reported as a synthetic compound, was isolated from fungal culture broth as an inhibitor of hatch and growth of Caenorhabditis elegans. Nineteen MPO derivatives were chemically synthesized, but showed no effect on C. elegans hatch and growth. These findings strongly suggested that the whole structure of MPO is essential for anti-C. elegans activity.

Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase

The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins that are degraded and/or otherwise inhibited by bifunctional compounds of the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand that binds to the ubiquitin ligase and on the other end a moiety that binds a target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds of the present invention, consistent with the degradation/inhibition of targeted polypeptides.

Is NMR fragment screening fine-tuned to assess druggability of protein-protein interactions?

Modulation of protein-protein interactions (PPIs) with small molecules has been hampered by a lack of lucid methods capable of reliably identifying high-quality hits. In fragment screening, the low ligand efficiencies associated with PPI target sites pose

Structure-guided design and optimization of small molecules targeting the protein-protein interaction between the von hippel-lindau (VHL) E3 ubiquitin ligase and the hypoxia inducible factor (HIF) alpha subunit with in vitro nanomolar affinities

E3 ubiquitin ligases are attractive targets in the ubiquitin-proteasome system, however, the development of small-molecule ligands has been rewarded with limited success. The von Hippel-Lindau protein (pVHL) is the substrate recognition subunit of the VHL E3 ligase that targets HIF-1α for degradation. We recently reported inhibitors of the pVHL:HIF-1α interaction, however they exhibited moderate potency. Herein, we report the design and optimization, guided by X-ray crystal structures, of a ligand series with nanomolar binding affinities.

COMPOUNDS AND METHODS FOR THE INHIBITION OF VCB E3 UBIQUITIN LIGASE

The present invention relates to novel compounds which find utility as modulators, especially inhibitors of VCB E3 Ubiquitin Ligase and as bioactive agents for use as therapeutics for the stimulation of erythropoiesis in a patient or subject including inducement of EPO production in the patient or subject, for the treatment of chronic anemia and ischemia (limits brain injury during episodes of localized anemia, ischemia and/or stroke and damage to cardiovascular tissue during cardiovascular ischemia), as well as enhancing wound healing processes. Pharmaceutical compositions comprising effective amounts of compounds according to the present invention alone or in combination with an additional erythropoieses stimulating agent such as EPO under the tradename procrit or epogen or darbapoietin alfa under the tradename aranesp. Methods of stimulating erythropoiesis in a subject or patient, including increasing the number of red blood cells and/or hematocrit of the patient, treating anemia, including chronic anemia and anemia associated with chronic kidney disease, dialysis, and cancer chemotherapy, ischemia, stroke and damage to cardiovascular tissue during cardiovascular ischemia as well as enhancing wound healing processes and preventing/reducing scarring secondary to healing represent additional aspects of the present invention. Local enhancement of angiogenesis through induction of VEGF including wound healing and reduction of stent occlusion remain additional aspects of the present invention.

Copper-mediated C-H/C-H biaryl coupling of benzoic acid derivatives and 1,3-azoles

Hot couple: A precious-metal-free copper-mediated intermolecular direct biaryl coupling of benzoic acid derivatives and 1,3-azoles has been developed. The key to success is the installation of an amide-based bidentate coordinating group, which is easily removed and transformed into the parent ester groups after the coupling reaction. Kinetic studies indicate that the rate-limiting step is the aromatic C-H bond cleavage of benzoic acid derivatives. Copyright